Natera Stock Falls 14.6% to $310.67 After Third Quarter Results, on 3.1 Times Usual Volume

1What Natera reported

Natera, Inc. (NTRA) closed down 14.6% on November 6, 2026, the session after it filed third quarter results with the SEC at 4:07 p.m. ET on Nov. 5, after the market closed. The results release covers the quarter ended September 30, 2026. The figures below sit beside the year earlier figure where the release prints one, and the release says its quarterly figures are unaudited, which means not yet finalized with the company's outside auditors.

• Revenue: $794.0 million in the third quarter, against $592.2 million in the third quarter of 2025, an increase of 34.1%.
• Gross profit: $513.5 million, against $384.4 million a year earlier. Gross margin, the share of revenue left after the direct cost of the tests, was 64.7%, against 64.9%.
• Estimate changes: Natera updated its estimates of what it will collect from payers for tests already billed. That added $32.3 million to revenue and gross profit in the 2026 quarter, against $55.1 million a year earlier.
• Loss: Loss from operations was $68.3 million, against $97.6 million a year earlier. Net loss was $59.9 million, or $0.42 per share, against $87.5 million, or $0.64 per share.
• Adjusted profit: The release prints no adjusted profit figure, which would be profit with some costs left out.
• Tests: Natera processed approximately 1,093,100 tests, against approximately 893,600 a year earlier. Oncology tests, which look for signs of cancer, were approximately 339,500, against approximately 211,000.
• Cash: About $1,097.2 million in cash, cash equivalents and restricted cash at September 30, 2026, against $1,076.1 million at December 31, 2025.
• Guidance: Natera raised its 2026 revenue guidance, its own forecast of sales for the year, by $140 million at the midpoint, which is the middle of the range. The range moved from $2.850 billion to $2.910 billion up to $3.005 billion to $3.035 billion. The release also gives gross margin of approximately 64% to 66% and positive cash flow, and it does not say whether those items changed.

2How the stock moved

Natera shares closed at $310.67 on Nov. 6, against a prior close of $363.76. The stock opened at $319.99, reached a high of $327.53 and a low of $304, then finished the session near the lower end of that range.

Volume, the number of shares that changed hands, was 5.8M. That is about 3.1 times its usual volume, measured by the 30 session average of 1.8M.

Other large companies in the same industry group, Services-Medical Laboratories as classed by the SEC, also traded that day. Labcorp Holdings (LH) rose 0.9% and Quest Diagnostics (DGX) rose 0.3%. These are the largest companies in that group, not chosen competitors, and their moves are listed here for reference only. A single day's move reflects that day's trading and can reverse or extend in later sessions.

3How this move compares

This table shows the stock's move on the first session after each of its last four results reports, with the latest report first.

The August move was a gain of 21.4% and the May move was a loss of 11.6%, so large moves on results day are not new for this stock. The February and January moves were smaller.

4What the rating read before the report

The Market Eyes rating on October 6, 2026, before the report, read Hold with a score of 67. Its strongest factor was Momentum at 84, which looks at how the share price has trended. Its weakest was Valuation at 39, which looks at the share price against company results. A rating describes conditions on the day it is read and is not a forecast.

5Words in this note

• Guidance: the company's own forecast of its results for a coming period.
• Gross margin: the share of revenue left after the direct cost of the tests.
• Volume: the number of shares that changed hands in a session.
• Unaudited: not yet finalized with the company's outside auditors.